Viatris Inc

$ 14.59

-1.08%

24 Apr - close price

  • Market Cap 17,175,208,000 USD
  • Current Price $ 14.59
  • High / Low $ 14.82 / 14.42
  • Stock P/E N/A
  • Book Value 12.78
  • EPS -3.00
  • Next Earning Report 2026-05-07
  • Dividend Per Share $0.48
  • Dividend Yield 3.31 %
  • Next Dividend Date -
  • ROA 0.02 %
  • ROE -0.21 %
  • 52 Week High 16.33
  • 52 Week Low 7.76

About

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Analyst Target Price

$15.72

Quarterly Earnings

Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Reported Date 2026-03-022025-11-062025-08-072025-05-072025-02-262024-11-072024-08-082024-05-092024-02-282023-11-072023-08-072023-05-08
Reported EPS 0.570.670.620.50.540.750.690.670.620.790.750.77
Estimated EPS 0.53480.620.550.49190.5720.680.680.670.650.740.710.69
Surprise 0.03520.050.070.0081-0.0320.070.010-0.030.050.040.08
Surprise Percentage 6.5819%8.0645%12.7273%1.6467%-5.5944%10.2941%1.4706%0%-4.6154%6.7568%5.6338%11.5942%

Next Quarterly Earnings

Mar 2026
Reported Date 2026-05-07
Fiscal Date Ending 2026-03-31
Estimated EPS 0.52
Currency USD

Previous Dividend Records

Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
Payment Date 2026-03-182025-12-152025-09-152025-06-162025-03-182024-12-132024-09-132024-06-142024-03-182023-12-15
Amount $0.12$0.12$0.12$0.12$0.12$0.12$0.12$0.12$0.12$0.12

Next Dividend Records

Dividend per share (year): -
Dividend Yield -
Next Dividend Date -
Ex-Dividend Date -

Recent News: VTRS

...
Viatris Inc. stock falls Friday, underperforms market

2026-04-24 17:10:00

Viatris Inc. (VTRS) stock declined by 1.08% on Friday, closing at $14.59, while the broader market showed mixed results. The S&P 500 Index rose, but the Dow Jones Industrial Average fell minimally. Viatris Inc. is now 11.41% below its 52-week high reached in February.

...
EMA Clears Path for Novartis To Expand Market For SMA Gene Therapy Itvisma

2026-04-24 14:08:59

The European Medicines Agency (EMA) has paved the way for Novartis to expand the market for its spinal muscular atrophy (SMA) gene therapy, Itvisma. The article suggests that Novartis's intrathecal formulation of the gene therapy could soon receive approval in the EU. This development is significant for Novartis and patients with SMA, potentially offering a new treatment option in Europe.

...
Viatris Inc. stock rises Thursday, outperforms market

2026-04-23 17:09:00

Viatris Inc. stock (VTRS) rose by 1.58% to $14.75 on Thursday, outperforming the broader market during a tough trading session. Both the S&P 500 Index and the Dow Jones Industrial Average experienced declines. This increase ended a two-day losing streak for Viatris.

...
Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap?

2026-04-23 14:40:40

Novo Nordisk's stock has crashed 72% from its peak, prompting questions about whether it's a buying opportunity or a value trap. The significant decline is attributed by the author to investor panic over increased competition and perceived decelerating growth in the GLP-1 market, rather than fundamental issues within the company. The article argues that Novo Nordisk's pipeline depth, broad market potential, and attractive valuation post-crash suggest it's a buying opportunity for long-term investors.

...
Deutetrabenazine Market to Witness Massive Growth by 2033 |Teva

2026-04-23 11:10:14

The global deutetrabenazine market is projected to grow from USD 1.08 billion in 2026 to USD 1.88 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 8.24%. A new report by Coherent Market Insights details this growth, including competitive analysis of key players like Teva Pharmaceutical Industries and Neurocrine Biosciences, market segmentation by indication, formulation, end-user, and distribution channel, and regional forecasts. The study also examines growth drivers, restraints, and opportunities within the market.

...
Viatris Inc. stock falls Wednesday, underperforms market

2026-04-22 17:12:00

Viatris Inc. (VTRS) stock declined by 1.43% on Wednesday, closing at $14.52. This performance was contrary to the broader market trend, as both the S&P 500 Index and the Dow Jones Industrial Average saw gains. This marks the second consecutive day of losses for Viatris.